Wednesday, October 7, 2015

FDA released a draft eCTD Technical Conformance Guide!

Here are some of the main points of the guide:

Transitioning to eCTD
  • Do not resubmit documents already submitted in paper or other electronic format. Provide only new or changed information.
  • You should not include the eCTD section number in the leaf title.
  • For documents of the same type (such as the cover letter, Form FDA 356h, and annual report documents), you should provide additional information in the eCTD leaf title so reviewers can distinguish documents submitted in different sequences. For example, the leaf title for a cover letter should also include the date (e.g., 2015-12-31).
  • If documents of the same type are being provided in different file formats, a file format (e.g., “MS Word”) should be included at the end of the leaf title.
Presubmissions
  • Any information submitted in eCTD format before the “original-application” should be coded as "presubmission" and should use sequence 0001. The original application will use the next available sequence number depending on the number of submitted “presubmissions.”
  • Signed FDA forms are not required for presubmissions. If you are going to submit using the Electronic Submission Gateway (ESG), include a completed fillable form without a signature. Fillable forms aid automated processing.
  • For INDs, the serial number field can be left blank for presubmissions and should be used only starting with the original application.
  • There is no requirement for the IND serial number and the eCTD sequence number to match.
Cover Letters
  • Technical description of the submission, including the approximate size of the submission (e.g., 2 gigabytes), the format used for transmission (ESG or physical electronic media), and the type and number of electronic media used (e.g., USB drive or two DVDs), if applicable
  • A regulatory and technical point of contact for the submission, including email address
Study Reports
  • For reports without a file tag, “study-report-body” can be applied as the file tag, with clear leaf title indicating content of the document.
  • If a document has been provided in a previous submission (e.g., protocol), provide only an eCTD leaf reference to the protocol in the eCTD backbone file, rather than resubmitting the protocol file.
Case Report Forms (CRFs)
  • FDA does not use the eCTD heading 5.3.7 for CRFs, therefore do not place files under this heading.
IND Safety Reports
  • Each individual IND safety report with its associated study should be provided in section 5.3 of the eCTD.
  • Each safety report should be referenced in the study’s STF using the ‘safetyreport’ file tag, with "Safety Report" in the eCTD leaf title along with "initial" or "follow-up," depending on the content of the individual safety report.
  • Each IND safety report should be submitted as “new” without replacing any previously submitted information. Leaf titles that clearly relate to the individual cases should be used.
Issues and Solutions

Issue: Combining Multiple 3.2.S or 3.2.P Sections With Similar Metadata
  • This issue is caused by leafs being submitted with incorrect metadata (‘name’, ‘manufacturer’, and/or ‘dosage form’ which are not an exact match to what was submitted previously).
Resolution
  • Use the eCTD “delete” operator to delete all the leaf IDs that were referenced in the section to be deleted. Deleting all leafs will remove the entire section from our review tool.
  • Re-reference the existing files using new leaf IDs, ensuring that the ‘name’, ‘manufacturer’, and/or ‘dosage form’ metadata is an exact match to the section where you want to re-add the leafs.
  • This issue is also caused when multiple 3.2.P sections were submitted for multiple strengths of the same drug product.
  • In general, when a single application for multiple strengths can be submitted, information for each of the product presentations and manufacturing schemes should be combined and presented together in one Drug Product section, with information for each of the product presentations and manufacturing schemes provided in the Appendices and Regional Information sections, as warranted.

The guide can be found in the following location:
http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/UCM465411.pdf

If you would like to help review and provide comments, please join the DIA ERS Community. 
https://siac-ers.diaconnex.org/


Friday, June 26, 2015

Process for converting a paper IND to eCTD



Question:

Can you please confirm the process for converting a paper IND to eCTD?

Response:

For transitioning to eCTD format from paper or non-eCTD format, the first submission would be coded according to the currently active regulatory activity. 

If you are transitioning your unapproved original application, you would code the us-regional.xml file as "original-application" as the submission-type for the first submission with a detailed explanation in the cover letter. 


If you are transitioning an approved original application, you would use "other" as the submission-type. If you are transitioning with the submission of a new supplement, you would use the appropriate supplement type (e.g. labeling supplement).

It's recommended that your transitioning eCTD sequence be identified as a general correspondence submission in the cover letter and FDA Form, stating the application will be submitted in eCTD format from this date forward. 

The FDA form should list the submission type as General Correspondence (Other). The bold print on the top of the cover letter should say the correct submission type (General Correspondence, Amendment, etc.). 

In the body or at the end of the cover letter, you could state the following:
"As per the advice received from Office of Business Informatics, this eCTD submission sequence is intentionally being coded as "other" in the us-regional.xml and serves as a first-level submission type in the Electronic Common Technical Document (eCTD) format. This eCTD sequence is intentionally being submitted as "other" to establish the eCTD hierarchal structure and will allow second-level submission types such as amendments and resubmissions to be related to it."  You should adjust the wording in your cover letter to match your specific situation.

If unable to submit a fully completed fillable form with an electronic digital signature, it is possible to submit the complete fillable form (not scanned) without the signature, along with a second 1571 form that uses another method for signatures (e.g., a scanned signature).

When including a second complete 1571 form (it can be scanned), do not include "1571" anywhere in the file name. We recommend that you use a filename such as "signed-form.pdf" or similar.  The filled form should be named "1571.pdf". This will allow our automated systems to correctly find your fillable form, read it, and process your submission appropriately. The project manager will be able to find your signed form near your filled form, in the module 1 forms section of the eCTD.  Both of these forms should be placed in section 1.1.1 for eCTD submissions.  

Tuesday, June 23, 2015

DIA Electronic Regulatory Submissions Community Monthly Meetings


The Electronic Regulatory Submissions Community meets the 4th Tuesday of each month at 11 am EST.

DIAL-IN INFORMATION
United States Toll Free
+1.866.668.0721

Participant code

1571310669

Tuesday, June 16, 2015

Electronic Regulatory Submissions Community Revival Survey

Hi all, 
The Core Committee of the DIA ERS Community has designed a short (9 question) survey to learn more about our stakeholders and the kind of information you are seeking.  Please fill out the short survey to help us https://www.surveymonkey.com/s/ers-revival.  
Thank you for your feedback!

Friday, June 12, 2015



If you haven't done so already, please join the DIA ERS community!

Drug Information Association Electronic Regulatory Submissions Community